Innate Pharma (IPHA) Income towards Parent Company (2018 - 2025)
Historic Income towards Parent Company for Innate Pharma (IPHA) over the last 8 years, with Q2 2025 value amounting to -$25.6 million.
- Innate Pharma's Income towards Parent Company rose 193.0% to -$25.6 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$51.2 million, marking a year-over-year decrease of 18360.01%. This contributed to the annual value of -$9.4 million for FY2024, which is 8309.53% up from last year.
- Per Innate Pharma's latest filing, its Income towards Parent Company stood at -$25.6 million for Q2 2025, which was up 193.0% from -$58.1 million recorded in Q4 2024.
- In the past 5 years, Innate Pharma's Income towards Parent Company registered a high of $7.5 million during Q2 2021, and its lowest value of -$131.3 million during Q4 2021.
- Its 5-year average for Income towards Parent Company is -$38.9 million, with a median of -$26.1 million in 2024.
- As far as peak fluctuations go, Innate Pharma's Income towards Parent Company surged by 89402.78% in 2023, and later plummeted by 432199.99% in 2024.
- Over the past 5 years, Innate Pharma's Income towards Parent Company (Quarter) stood at -$131.3 million in 2021, then surged by 57.92% to -$55.2 million in 2022, then decreased by 12.25% to -$62.0 million in 2023, then increased by 6.38% to -$58.1 million in 2024, then soared by 55.89% to -$25.6 million in 2025.
- Its Income towards Parent Company was -$25.6 million in Q2 2025, compared to -$58.1 million in Q4 2024 and -$26.1 million in Q2 2024.